Arrowhead Pharmaceuticals, Inc. (ARWR)

Market Cap	3.05B
Revenue (ttm)	572.98M
Net Income (ttm)	-148.42M
Shares Out	138.26M
EPS (ttm)	-1.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,388,674
Open	22.43
Previous Close	22.03
Day's Range	21.61 - 22.55
52-Week Range	9.57 - 27.34
Beta	1.01
Analysts	Buy
Price Target	43.14 (+95.82%)
Earnings Date	Aug 7, 2025

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 1993
• Employees: 609
• Stock Exchange: NASDAQ
• Ticker Symbol: ARWR
• Website: https://arrowheadpharma.com

Financial Performance

In 2024, Arrowhead Pharmaceuticals's revenue was $3.55 million, a decrease of -98.52% compared to the previous year's $240.74 million. Losses were -$599.49 million, 192.0% more than in 2023.

Analyst Summary

According to 8 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price target is $43.14, which is an increase of 95.82% from the latest price.

Price Target

$43.14

(95.82% upside)

Analyst Consensus: Buy